Advanced Tissue Sciences Pursuing Dermagraft Cardiac Indications
This article was originally published in The Gray Sheet
Executive Summary
Pursuit of cardiovascular indications for Advanced Tissue Sciences' Dermagraft fibroblast tissue repair technology is likely to hinge upon finding a joint venture partner for the product, according to the La Jolla, California-based company.
You may also be interested in...
Smith & Nephew Buys Wound Care Line, Looks To Streamline Operations
Smith & Nephew's bid to bolster its medical device businesse involves a three-pronged strategy to acquire an advanced wound care product, divest its consumer businesses, and form a joint venture for its traditional wound care products.
Smith & Nephew Buys Wound Care Line, Looks To Streamline Operations
Smith & Nephew's bid to bolster its medical device businesse involves a three-pronged strategy to acquire an advanced wound care product, divest its consumer businesses, and form a joint venture for its traditional wound care products.
FDA Halts Vascular Genetics VEGF-2 Gene Therapy Heart Disease Trial
FDA has placed a gene therapy trial to promote angiogenesis in coronary heart disease patients on clinical hold. The study was being conducted by Vascular Genetics Inc., under the leadership of Jeff Isner, MD, chief of cardiovascular medicine at St. Elizabeth's Medical Center in Boston.